Tuberculosis News and Research

Latest Tuberculosis News and Research

Shire Canada supports initiative for further access to antiretroviral medicine for Rwanda

Shire Canada Inc., a division of Shire plc, announced today its voluntary cooperation to enable further royalty-free access to HIV/AIDS medicines for Rwanda as part of ongoing collaborative efforts to improve health and save lives in the developing world.

20 Oct 2009

Opinions: HIV vaccine; HIV resources help promote global disease control; U.S. fight against world hunger

Seth Berkley, president and chief executive of the International AIDS Vaccine Initiative, in a New York Times opinion piece examines how the "pessimism" over the recent controversy surrounding the results of an experimental HIV vaccine tested in Thailand "may ultimately thwart other efforts to develop an AIDS vaccine.

20 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

19 Oct 2009

Recent releases in global health

In light of a recent Guttmacher Institute report that indicated 70,000 women in developing countries die each year from unsafe abortion, a Lancet editorial outlines ways to reduce deaths, and says, "The current political climate is favourable, because the global-gag rule (the U.S. Government's policy on banning funding of foreign organisations linked to any type of abortion practice) is out of favour" (10/17).

19 Oct 2009

Also in global health news: Street pharmacies; China health care; Hospital safety; African cardinals; Cells phones for health

Agence France-Presse examines Adjegounle, the "drugs" district in Benin. Although some are able to support their families by selling drugs at "street pharmacies," a minimum of "250 deaths and 340 cases of chronic illnesses linked to such drugs were recorded between April 2007 and June 2008," according to a medical thesis, the news service writes.

19 Oct 2009

Chembio Diagnostics to supply over 2000 PrimaTB STAT-PAK tuberculosis testing kits

Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has agreed to provide over 2,000 PrimaTB STAT-PAK tuberculosis (TB) testing kits which are approved for use in Macaques to the Orangutan Conservancy (OC) to support the organization's continued drive to raise the level of veterinary care at orangutan rehabilitation centers.

19 Oct 2009

Roundtable discussion to elevate awareness about the importance of biopreparedness

Emergent BioSolutions Inc. was pleased to sponsor the Security and Defence Agenda’s (SDA) roundtable discussion, “Raising Biopreparedness Levels in Europe,” which examined European efforts in preparing and reacting to various biological threats and the potential for European cooperation in these areas.

19 Oct 2009

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

BioMedReports.Com releases an exclusive interview with spokesman for Biomagnetics Diagnostics

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has released an exclusive interview with a spokesman for Biomagnetics Diagnostics Corp., the company behind a revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis field testing.

15 Oct 2009

News outlets examine efforts to control TB in South Africa

Agence France-Presse examines the ongoing fight to control the spread of tuberculosis in South Africa. "The World Health Organisation estimates almost one percent or 461,000 South Africans develop TB annually, with government figures showing that the disease was the country's leading natural cause of death in 2006," the news service writes.

15 Oct 2009

Fero Industries to acquire Pyro Pharmaceuticals

Fero Industries, Inc. (the “Company”) is pleased to announce that the Company has entered into a Definitive Agreement to acquire Pyro Pharmaceuticals, Inc. of Irvine, California.

15 Oct 2009

BioMedReports electronic newsletter releases an article about Biomagnetics Diagnostics

Biomagnetics Diagnostics Corp., a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV, and hepatitis testing, today announced the Company is the subject of a cover page story in the prestigious BioMedReports electronic newsletter and portal.

14 Oct 2009

African leaders, Chirac unite to fight fake drug manufacturing, distribution

Leaders from Benin, Burkina Faso, the Central African Republic, Congo-Republic, Niger and Senegal on Monday joined former French President Jacques Chirac in Cotonou, Benin, in a campaign against the manufacturing and sale of fake pharmaceutical products, Reuters reports (Lewis, 10/12).

14 Oct 2009

Sequella receives Phase 1 SBIR grant for developing SQ641

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.

13 Oct 2009

Also in global health news: HIV immigration rules; Global Fund Aid in Kenya; water shortage in Yemen; testing for TB

NPR examines U.S. policy for HIV-positive visitors and immigrants. While "Congress has removed the statute, and the Department of Health and Human Services is working on a more lenient immigration rule,"

12 Oct 2009

Recent releases in Global Health

A Lancet comment examines an Affordable Medicines Facility for malaria (AMFm) program to help countries procure subsidized artemisinin-based combination treatments (ACTs).

9 Oct 2009

VOA News examines U.S. global health funding

VOA News examines how the recession will be a factor in U.S. funding decisions about PEPFAR and other global health initiatives. According to VOA, the Obama administration's proposed funding for HIV, tuberculosis and malaria in 2010 is "higher than the current fiscal year. However, the proposed increase is lower than in some years past."

9 Oct 2009

Researchers to develop new technique to detect tuberculosis in developing countries

Two billion people worldwide carry the pathogen that causes tuberculosis (TB), and most of them do not even know they are infected. This is because some 90 percent of people with TB have "latent" infections. They have no symptoms, they can't spread the disease to others and the bug remains dormant in their lungs -- often for years.

9 Oct 2009

U.S. should provide more leadership in finding TB vaccine, opinion piece says

Tuberculosis deserves an effort as "substantial" as the one mounted against swine flu "to develop a new vaccine," David McMurray, a TB expert at Texas A&M University System Health Science Center, writes in a Houston Chronicle opinion piece.

9 Oct 2009

Tuberculosis News and Research

Latest Tuberculosis News and Research

Shire Canada supports initiative for further access to antiretroviral medicine for Rwanda

Opinions: HIV vaccine; HIV resources help promote global disease control; U.S. fight against world hunger

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

Recent releases in global health

Also in global health news: Street pharmacies; China health care; Hospital safety; African cardinals; Cells phones for health

Chembio Diagnostics to supply over 2000 PrimaTB STAT-PAK tuberculosis testing kits

Roundtable discussion to elevate awareness about the importance of biopreparedness

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

BioMedReports.Com releases an exclusive interview with spokesman for Biomagnetics Diagnostics

News outlets examine efforts to control TB in South Africa

Fero Industries to acquire Pyro Pharmaceuticals

BioMedReports electronic newsletter releases an article about Biomagnetics Diagnostics

African leaders, Chirac unite to fight fake drug manufacturing, distribution

Sequella receives Phase 1 SBIR grant for developing SQ641

Also in global health news: HIV immigration rules; Global Fund Aid in Kenya; water shortage in Yemen; testing for TB

Recent releases in Global Health

VOA News examines U.S. global health funding

Researchers to develop new technique to detect tuberculosis in developing countries

U.S. should provide more leadership in finding TB vaccine, opinion piece says

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Tuberculosis News and Research

Latest Tuberculosis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in